Cytokine Release Syndrome

An ongoing proof-of-concept clinical trial is underway to assess the use of a novel T-cell therapy for the treatment of advanced hepatocellular carcinoma.

ORLANDO — About 20% of a cohort of patients with aggressive relapsed or refractory non-Hodgkin lymphoma experienced complete response to treatment with the investigational agent mosunetuzumab, according to updated data from a phase 1/phase 1b dose-escalation and dose-expansion study presented during the plenary session of ASH Annual Meeting and Exposition.

ORLANDO — Early steroid use appeared to reduce the incidence of severe cytokine release syndrome and neurotoxicity without affecting response rates in patients with relapsed/refractory large B-cell lymphoma who received CAR T-cell treatment, according to study results presented in a video at ASH Annual Meeting and Exposition.

Children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia reported sustained, clinically meaningful improvement in quality-of-life scores after receiving chimeric antigen receptor T-cell therapy, according to an analysis of the single-arm, phase 2 ELIANA trial published in The Lancet Oncology.

Imagine a young adult male in his late 20s picks up his cell phone and calls his mother. Overtly emotional and on the verge of releasing a full-out flow of tears, the young man says to the voice at the other end of the line, “Mom, there’s hope.”

Patients who received radiation therapy before chimeric antigen receptor T-cell therapy for relapsed or refractory non-Hodgkin lymphoma were less likely to have severe treatment-related toxicities, according to results of a study presented at the American Society of Radiation Oncology Annual Meeting.